A5034215926- Histone Deacetylase Inhibitors Research
- Synthesis and biological activity
- Peptidase Inhibition and Analysis
- Synthesis and Biological Evaluation
- Quinazolinone synthesis and applications
- Synthesis and Characterization of Heterocyclic Compounds
- Protein Degradation and Inhibitors
- Click Chemistry and Applications
- Glioma Diagnosis and Treatment
- Biochemical and Molecular Research
- Computational Drug Discovery Methods
- Bioactive Compounds and Antitumor Agents
- Epigenetics and DNA Methylation
- PARP inhibition in cancer therapy
- Synthesis and bioactivity of alkaloids
- Gout, Hyperuricemia, Uric Acid
- Fungal Plant Pathogen Control
- Heat shock proteins research
- Synthesis of Organic Compounds
- Cholinesterase and Neurodegenerative Diseases
- Carbohydrate Chemistry and Synthesis
- ATP Synthase and ATPases Research
- Phenothiazines and Benzothiazines Synthesis and Activities
- Cancer Mechanisms and Therapy
- Enzyme function and inhibition
Taipei Medical University
2016-2025
Guru Nanak Dev University
2012-2017
Indian Institute of Management Amritsar
2017
Indo Soviet Friendship College of Pharmacy
2010-2015
Punjab Technical University
2014
Lovely Professional University
2010
Rabindranath Tagore Medical College
2010
Pharmaceutical Biotechnology (Czechia)
2010
Bharti Hospital
2008
The nitro group is considered to be a versatile and unique functional in medicinal chemistry. Despite long history of use therapeutics, the has toxicity issues often categorized as structural alert or toxicophore, evidence related drugs containing groups rather contradictory. In general, have been extensively associated with mutagenicity genotoxicity. this context, efforts toward structure–mutagenicity structure–genotoxicity relationships undertaken. current Perspective covers various...
Pyran-based heterocycles are promising for anticancer drug discovery.
A series of bicyclic arylamino/heteroarylamino hydroxamic acids (7–31) have been examined as novel histone deacetylase 6 (HDAC6) inhibitors. One compound (13) exhibits remarkable inhibitory activity HDAC6 with an IC50 value 0.29 nM, which is 4,000–43,000 times more selective over other HDAC isoforms. Compound 13 was shown to antiproliferative against human multiple myeloma RPMI 8226, U266, and NCI-H929 cells no effect on normal bone marrow cells. 13, a single drug, suppresses the growth...
Structural analysis of tazemetostat, an FDA-approved EZH2 inhibitor, led us to pinpoint a suitable site for appendage with pharmacophoric fragment second-generation HSP90 inhibitors. Resultantly, magnificent dual EZH2/HSP90 inhibitor was pinpointed that exerted striking cell growth inhibitory efficacy against TMZ-resistant Glioblastoma (GBM) lines. Exhaustive explorations chemical probe 7 several revelations such as (i) compound increased apoptosis/necrosis-related gene expression, whereas...
The combretastatins are a class of natural stilbenoids. These molecules generally share three common structural features: trimethoxy "A"-ring, "B"-ring containing substituent often at C3' and C4', an ethene bridge between the two rings, which provides necessary rigidity. Members combretastatin family possess varying ability to cause vascular disruption in tumors. Combretastatin binds colchicine binding site β-subunit tubulin. Despite having similar name, is unrelated statins,...
Pragmatic insertion of pargyline, a LSD1 inhibitor, as surface recognition part in the HDAC inhibitory pharmacophore was planned pursuit furnishing potent antiprostate cancer agents. Resultantly, compound 14 elicited magnificent cell growth effects against PC-3 and DU-145 lines led to remarkable suppression tumor human prostate xenograft nude mouse models. The outcome enzymatic assays ascertained that substantial antiproliferative were mediated through HDAC6 isoform inhibition well selective...